Planned
ASCENDIS
A Randomized, Phase 2, Open-label Study of TransCon IL-2 β/γ Monotherapy, TransCon IL-2 β/γ in Combination with TransCon TLR7/8 Agonist, TransCon TLR7/8 Agonist in Combination with Pembrolizumab, or Pembrolizumab Monotherapy as Neoadjuvant Therapy in Participants with Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
- Principal investigator : Prof. Dr. Paul Clement
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT05081609
Ongoing
ASPEN-03 AT148003
A Phase 2 Study of ALX148 in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamos Cell Carcinoma
- Principal investigator : Prof. Dr. Paul Clement
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT04675294
ELEVATE 5916 GS-US-548-5916
A Phase 2 Study of Magrolimab Combination Therapy in Patients
With Head and Neck Squamous Cell Carcinoma
- Principal investigator : Prof. Dr. Paul Clement
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
GS-US-548-5916
A Phase 2 Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma
- Principal investigator : Prof. Dr. Paul Clement
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT04854499
UPSTREAM EORTC-1559-HNCG
A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
- Principal investigator : Prof. Dr. Paul Clement
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT03088059
Closed
AIM-HN & SEQ-HN KO-TIP-007
A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)
- Principal investigator : Prof. Dr. Paul Clement
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT03719690
CDI-CS-002
An Open-label Phase 1/2a Study of Oral BAL101553 in Adult Patients With Advanced Solid Tumors and in Adult Patients With Recurrent or Progressive Glioblastoma or High-grade Glioma
- Principal investigator : Prof. Dr. Paul Clement
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT02490800
DUTRELASCO ESR-16-12192
Durvalumab plus Tremelimumab in resectable, locally advanced squamous cell carcinoma of the head and neck: a window of opportunity study
- Principal investigator : Prof. Dr. Paul Clement
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT03784066
EORTC 1206
A randomized phase II study to evaluate the efficacy and safety of chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing, salivary gland cancer (SGCs)
- Principal investigator : Prof. Dr. Paul Clement
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT01969578
EAGLE D4193C00002
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Principal investigator : Prof. Dr. Paul Clement
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT02369874
INDUCE-4
A Randomized, Double-Blind, Phase III Study of GSK3359609 in Combination with Pembrolizumab and Platinum-based Chemotherapy versus Placebo in combination with Pembrolizumab plus Platinum-based Chemotherapy for First-Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Principal investigator : Prof. Dr. Paul Clement
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT04428333
INTERLINK-I
Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination with Cetuximab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor.
- Principal investigator : Prof. Dr. Paul Clement
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT04590963
KEYNOTE-412 MK-3475-412
A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma
- Principal investigator : Prof. Dr. Paul Clement
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT03040999
LUZERA-301 ASP-1929-301
Phase 3 Randomized, Double-Arm, Open-Label, Controlled Trial of ASP-1929 Photoimmunotherapy Versus Standard of Care for Locoregional Recurrent Head/Neck Squamous Cell Carcinoma in Patients Who Have Failed After at Least Two Lines of Therapy
- Principal investigator : Prof. Dr. Paul Clement
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT03769506
OPCEMISA ISA101b-HN-01-17
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study of Cemiplimab Versus the Combination of Cemiplimab With ISA101b in the Treatment of Subjects With HPV16-Positive Platin-Resistant Oropharyngeal Cancer (OPC)
- Principal investigator : Prof. Dr. Paul Clement
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT03669718
WAVE D910FC00001
An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who Are Receiving or Who Previously Received Durvalumab in Other Protocols
- Principal investigator : Prof. Dr. Paul Clement
- Back-up principal investigator : Prof. Dr. Patrick Schöffski
- More information : NCT04078152